about
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness researchPilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing.Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML.Systematic review of pharmacoeconomic studies of pharmacogenomic tests.Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications.The economic considerations and implications of the stratification of future oncology therapeutics.Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality.How the science of personalized medicines will change the clinical management of patients in the pharmacy.A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.Exploring rates of abnormal pharmacogenetic findings in a pain practice.Pharmacogenomics: "noninferiority" is sufficient for initial implementation.Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results.Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance
P2860
Q30419845-10BDC669-5EF4-4B2B-ADB7-8CF9CCAAE915Q30612258-F4EBDF92-C055-416E-8EAA-B45DEAEA401EQ35925229-D2050AD7-145C-4EBC-BE2B-1AB4FBE227ECQ36185299-C0486203-2514-413F-9EC4-5FCCA899C78CQ37814401-A54E7C2E-7B04-48AB-907E-ED11C872DBA6Q37866805-C8976C82-8F0F-45E6-8571-B979003CD98DQ38211622-FF6EF54D-7B5D-4BB3-BC34-8B662289E642Q38671676-D595629F-05E2-4CD2-B9C4-D37D33B1F99EQ38777644-2E245D75-0806-45D1-AC67-132499FF378DQ38904691-BE511383-B2FF-41CB-9684-1F2918A9AFCEQ39519107-A52D481A-CDA8-47B2-A10D-DA1C43908AAEQ40549451-9A1B15C3-0C71-40C2-A4DD-91476A5AA55BQ45770718-E03CAB11-CEE7-45BF-B7C9-17289E15FECCQ46404559-DC69815E-C9E5-4431-9824-08C645C980AEQ47157497-F68F681A-7A07-4A9C-A577-303EDC1CC7FEQ53088528-2BE37013-3D6C-4A33-9FD1-68CB5633891EQ57261679-14855B84-9A54-4EED-A8F6-74888D904E7D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness analysis in pharmacogenomics.
@en
Cost-effectiveness analysis in pharmacogenomics.
@nl
type
label
Cost-effectiveness analysis in pharmacogenomics.
@en
Cost-effectiveness analysis in pharmacogenomics.
@nl
prefLabel
Cost-effectiveness analysis in pharmacogenomics.
@en
Cost-effectiveness analysis in pharmacogenomics.
@nl
P2860
P356
P1433
P1476
Cost-effectiveness analysis in pharmacogenomics.
@en
P2093
Fatiha H Shabaruddin
Katherine Payne
P2860
P304
P356
10.2217/PGS.10.45
P577
2010-05-01T00:00:00Z